Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21983370 | 0.92 | GAA (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL26192490 | 0.92 | GAA (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL17521943 | 0.92 | STING1 (0.33) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL16751457 | 0.92 | LMNA (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL6895085 | 0.92 | EPHX2 (0.35) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL25334575 | 0.92 | ALDH1A1 (0.41) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL12348352 | 0.90 | STING1 (0.34) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL24894291 | 0.89 | FDPS (0.36) | ALDH1A1 | |
| SCHEMBL16334546 | 0.86 | STING1 (0.36) | STING1HDAC1HDAC2HDAC6HDAC3 | |
| SCHEMBL3960043 | 0.86 | GRM4 (0.37) | STING1HDAC1HDAC2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2804832-B1 | REVERSIBLE SWITCHING BETWEEN SUPER HYDROPHOBIC AND SUPER HYDROPHILIC STATES | COUNCIL SCIENT IND RES (IN) | 2018-04-18 | — | — | EP | claimed |
| EP-2804832-A1 | REVERSIBLE SWITCHING BETWEEN SUPER HYDROPHOBIC AND SUPER HYDROPHILIC STATES | Council of Scientific & Industrial Research (IN) | 2014-11-26 | — | — | EP | claimed |
| WO-2013108199-A1 | REVERSIBLE SWITCHING BETWEEN SUPER HYDROPHOBIC AND SUPER HYDROPHILIC STATES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-25 | — | — | WO | claimed |
| EP-4737504-A2 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4276090-B1 | CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-04-29 | — | — | EP | disclosed |
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4594354-A1 | ANTIBODY DRUG CONJUGATES TARGETING C-MET AND METHODS OF USE | Zymeworks BC Inc. (CA) | 2025-08-06 | — | — | EP | disclosed |
| US-20250222128-A1 | ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOF | ZYMEWORKS BC INC. (CA) | 2025-07-10 | — | — | US | disclosed |
| US-20250215042-A1 | MANNOSE-TARGETED COMPOSITIONS | GENEVANT SCIENCES GMBH (CH) | 2025-07-03 | — | — | US | disclosed |
| US-20250179496-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | Carbometrics Limited (GB) | 2025-05-29 | — | — | US | disclosed |
| EP-0771190-A4 | LOCK AND KEY MICELLES | UNIV SOUTH FLORIDA (US) | 2000-12-20 | — | — | EP | disclosed |
| US-6130209-A | Lock and key micelles | UNIVERSITY OF SOUTH FLORIDA (US) | 2000-10-10 | — | — | US | disclosed |
| US-5863919-A | Lock and key micelles and monomer building blocks therefor | UNIVERSITY OF SOUTH FLORIDA (US) | 1999-01-26 | — | — | US | disclosed |
| US-5650101-A | Lock and key micelles | UNIVERSITY OF SOUTH FLORIDA (US) | 1997-07-22 | — | — | US | disclosed |
| EP-0771190-A1 | LOCK AND KEY MICELLES | UNIVERSITY OF SOUTH FLORIDA (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996003114-A1 | LOCK AND KEY MICELLES | UNIVERSITY OF SOUTH FLORIDA (US) | 1996-02-08 | — | — | WO | disclosed |
| EP-0638060-A4 | T-BUTYL CASCADE POLYMERS. | UNIV SOUTH FLORIDA (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0638060-A1 | T-BUTYL CASCADE POLYMERS | UNIVERSITY OF SOUTH FLORIDA (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993021144-A1 | T-BUTYL CASCADE POLYMERS | UNIVERSITY OF SOUTH FLORIDA (US) | 1993-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222128-A1 | ANTIBODY DRUG-CONJUGATES TARGETING C-MET AND METHODS OF USE THEREOF | MET, MMAB, CEPT1 | STING1 4236/4885HDAC1 3489/4885HDAC2 4234/4885 |
| US-20250172566-A1 | SACCHARIDE SENSING SYSTEMS | GALE, SLC2A8, SLC2A4 | STING1 2825/4885HDAC1 413/4885HDAC2 1332/4885 |
| US-20250215042-A1 | MANNOSE-TARGETED COMPOSITIONS | MAN2A1, M6PR, MANBA | STING1 3696/4885HDAC1 1398/4885HDAC2 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.